Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T22:23:54.571Z.
Calculation as of: 2026-10-06T22:23:54.571Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7c85ff734d2850511ecc65d4372fb375f497d0f47939b952c94dba1281e34a39
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$52.60M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tenax Therapeutics, Inc. (TENX) | $51.19M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $51.88M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $50.28M | 8.52x | 5.77x | 8.01x | 6.98x |
| Envoy Medical, Inc. (COCH)vs › | $50.27M | N/A | N/A | N/A | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $49.71M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
